人民财讯9月19日电，赛升药业（300485）9月19日公告，股东马丽、刘淑芹分别持股2984.68万股、 874.8万股，持股比例分别为6.2%、1.82%，计划通过集中竞价和大宗交易合计减持不超过963.33万股， 即不超过2%。马丽和刘淑芹均为公司控股股东、实际控制人马骉先生的一致行动人。 ...

Core Viewpoint - The announcement from Sai Sheng Pharmaceutical indicates that two significant shareholders plan to reduce their holdings, which may impact the company's stock performance and investor sentiment [1] Group 1: Shareholder Actions - Ms. Ma Li holds approximately 29.85 million shares, accounting for 6.2% of the total share capital of about 482 million shares [1] - Ms. Liu Shuqin holds approximately 8.75 million shares, representing 1.82% of the total share capital [1] - Both shareholders plan to reduce their combined holdings by up to approximately 9.63 million shares, not exceeding 2% of the total share capital, within three months after the announcement [1] Group 2: Company Financials - For the year 2024, the revenue composition of Sai Sheng Pharmaceutical is projected to be 99.63% from the pharmaceutical manufacturing sector and 0.37% from other businesses [1] - As of the announcement, the market capitalization of Sai Sheng Pharmaceutical is 5.8 billion yuan [1]

赛升药业（300485）(300485.SZ)公告，公司股东马丽女士和刘淑芹女士计划在2025年10月21日至2026 年1月20日通过集中竞价和大宗交易方式减持公司股份数量合计不超过963.33万股，即不超过公司当前 总股本的2%。 ...

Group 1 - The core point of the article is that shareholders of Sai Sheng Pharmaceutical plan to reduce their holdings by a total of up to 9.633 million shares, which represents no more than 2% of the company's current total share capital [1] Group 2 - The reduction in shareholding will occur between October 21, 2025, and January 20, 2026, through centralized bidding and block trading methods [1]

证券代码：300485 证券简称：赛升药业 公告编号：2025-036 北京赛升药业股份有限公司 关于公司控股股东、实际控制人的一致行动人 减持股份的预披露公告 马丽女士和刘淑芹女士计划在自本公告披露之日起 15 个交易日后的 3 个月 内（即：2025 年 10 月 21 日至 2026 年 1 月 20 日），通过集中竞价和大宗交易 方式减持公司股份数量合计不超过 9,633,328 股，即不超过公司当前总股本 481,666,400 股的 2%。 近日，北京赛升药业股份有限公司（以下简称"公司"或"赛升药业"）收 到马丽女士、刘淑芹女士出具的《股份减持计划告知函》，现将有关情况公告如 下： 一、股东的基本情况 | 序号 | 股东名称 | 股东类型/职务 | 持有公司股份 的总数量（股） | 占公司总股 本的比例 | | --- | --- | --- | --- | --- | | 1 | 马丽 | 持股 5%以上股东、公司实际控制人的 一致行动人、董事、高级管理人员 | 29,846,791 | 6.2% | | 2 | 刘淑芹 | 公司实际控制人的一致行动人 | 8,748,000 | 1.82% ...

Core Insights - The company, Sai Sheng Pharmaceutical, reported that as of September 10, 2025, the number of shareholders is 34,261 [2] Company Summary - Sai Sheng Pharmaceutical has engaged with investors through an interactive platform, providing updates on shareholder numbers [2]

Group 1 - The company, Sai Sheng Pharmaceutical, reported that as of August 29, 2025, the number of shareholders is 34,632 [1]

Market Overview - The biopharmaceutical sector experienced a slight increase of 0.0% on September 12, with Aopumai leading the gains [1] - The Shanghai Composite Index closed at 3883.69, up by 0.22%, while the Shenzhen Component Index closed at 12996.38, up by 0.13% [1] Top Gainers in Biopharmaceutical Sector - Aopumai (688293) closed at 54.00, with a rise of 4.73% and a trading volume of 20,300 lots, totaling a transaction value of 103 million [1] - Kexing Pharmaceutical (688136) closed at 42.28, increasing by 3.45% with a trading volume of 47,400 lots, amounting to 197 million [1] - Sanofi (688336) closed at 57.07, up by 3.39% with a trading volume of 52,600 lots, totaling 294 million [1] - Tibet Pharmaceutical (600211) closed at 56.60, rising by 3.38% with a trading volume of 93,300 lots, totaling 510 million [1] - Wenqu Pharmaceutical (688488) closed at 16.00, increasing by 2.83% with a trading volume of 86,300 lots, amounting to 134 million [1] Top Decliners in Biopharmaceutical Sector - Rongchang Biopharmaceutical (688331) closed at 107.22, down by 2.68% with a trading volume of 56,400 lots, totaling 611 million [2] - Wanze Shares (000534) closed at 16.02, decreasing by 2.61% with a trading volume of 135,500 lots, amounting to 218 million [2] - Kangtai Biopharmaceutical (300601) closed at 18.63, down by 1.48% with a trading volume of 156,700 lots, totaling 292 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 310 million from institutional investors, while retail investors experienced a net inflow of 132 million [2] - Notable net inflows from retail investors were observed in Kanghua Biological (300841) with 94.86 million, and Xizang Pharmaceutical (600211) with 49.76 million [3] - Conversely, significant net outflows were noted in Rongchang Biopharmaceutical (688331) with 17.13 million and Aopumai (688293) with 18.19 million from retail investors [3]

致：北京赛升药业股份有限公司 北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于北京赛升药业股份有限公司 2025 年第一次临时股东大会的法律意见书 康达股会字【2025】第 0372 号 3、本所律师同意将本法律意见书作为公司本次会议的必备文件公告，并依法对本 所出具的法律意见承担责任。 本所律师已经对与出具法律意见书有关的所有文件材料进行核查，现场见证了本 次会议并据此出具法律意见如下： 一、本次会议的召集、召开程序 （一）本次会议的召集 根据《中华人民共和国公司 ...

证券代码:300485 证券简称：赛升药业 公告编号：2025-035 北京赛升药业股份有限公司 2025 年第一次临时股东大会决议公告 （一）会议召开情况： 1、会议召集人：公司董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更议案的情形。 2、本次股东大会不涉及变更前次股东大会决议的情形。 3、本次股东大会采取现场投票与网络投票相结合的表决方式。 一、会议召开和出席情况 2、会议方式：本次会议采取现场投票和网络投票相结合的方式 3、会议召开时间： （1）现场会议召开时间为：2025 年 9 月 8 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 9 月 8 日 9:15-9:25、9:30-11:30 和 13:00-15:00；通过互联网投 票系统投票的具体时间为：2025 年 9 月 8 日 9:15-15:00 任意时间。 4、会议地点：北京市北京经济技术开发区兴盛街 8 号 5、会议主持人：董事长马骉先生 6、本次会议的召集、召开符合《公司法》 ...